Infliximab salvage in treatment of refractory ulcerative colitis

LU Xiaojuan,SHENG Jianqiu,LI Shujun,FAN Ruying,WANG Jiheng,YANG Xinyan,FU Lei,WANG Xiaowei,LI Shirong
DOI: https://doi.org/10.3969/j.issn.1006-5709.2012.08.023
2012-01-01
Abstract:Objective To assess the efficacy and safety of infliximab therapy in Chinese patients with refactory moderate to severe ulcerative colitis.Methods 14 patients with moderate to severe active ulcerative colitis,who had active disease despite treatment with conventional therapy,mostly recerived infliximab(5 mg/kg) intravenously at the 0,2,6 weeks,and then every 8 weeks,while few patients increased dosage or shortened use interval.The clinical data of 14 cases were retrospectively analyzed,including effective rate and remission rate at week 8,remission rate at follow-up 30 and 54 weeks respectively,as well as safety.Results The clinical effective rate was 42.9% and remission rate was 42.9% at 8 weeks,clinical remission rates are 57.1% at week 30 and 42.3% at week 54.Two patients achieved mucosa healing.The rate of adverse events was 28.6%(4 cases).Among the 14 patients,no serious adverse events happened.Patients who achieved response after the first two infliximab infusion were more likely to have a clinical response at week 54(P=0.015).Conclusion Treatment with infliximab in the 14 patients with refractory ulcerative colitis is effective,and have high safety in short term.The first two times effective treatment could indicate good therapy effect in long-term follow-up.Therefore,infliximab could be used as salvage therapy in refractory ulcerative colitis.
What problem does this paper attempt to address?